GenAI simplifies data analysis, speeds investigations, enables real-time CPV with predictive monitoring, and streamlines APQRs by unifying data across systems.
CPV data and reporting are used in APQR but the programs are usually not aligned causing duplicate work. Integrating CPV and APQR with unified data, automated data gathering, and analytics improves operational efficiency.
Joint webinar with Agilent Technologies: Use case demonstrating the utility of on-line HPLC to monitor and control antibody aggregation levels in bioprocessing.
Case studies on the implementation of Raman spectroscopy for monitoring in bench-scale CHO cell intensified seed trains (N-1), steady state and dynamic perfusion (N) cultures. Understand the value of combining automated sampling with Raman spectroscopy for increased sample frequency, leading to more accurate measurement of CPPs and CQAs in upstream bioprocesses.
Automated sampling system and its utilization in perfusion cell culture for upstream process development reducing the time to measure CQAs and manual labor, accelerating access to analytical data, and decreasing risk.
A bioprocessing technique where multiple columns are loaded in series and then cycled for elution, regeneration, and equilibration allowing fuller utilization of the potential resin binding capacity, and rapid cycling of much smaller columns suitable for continuous bioprocessing.
This webinar explores how automation strategies and control schemes facilitate rapid analytical results, crucial for managing glycosylation variability that affects product quality.
The use of induced pluripotent stem (iPS) cell–derived therapies has such potential to expand the types of indications that may be treated via cellular therapy.
Industry 4.0, conceptualized by the digitalization-led convergence of digital, physical, and virtual assets, brings a paradigm shift in the totality of operations across the value chain.
Medicines derived from biological compounds are the fastest-growing class of drugs. We discuss how to accelerate the production of these biologics to a rapid pace.
